LOS ANGELES, April 28, 2015 (GLOBE NEWSWIRE) -- BioSig Technologies (OTCQB: BSGM) executive leadership will be attending the Heart Rhythm Society's 36th Annual Scientific Sessions from May 13 – 16 in Boston, Massachusetts.
In the rapidly evolving field of electrophysiology, staying current with the latest developments is key to advancing patient care. Through more than three days of learning, physicians, allied health care professionals, and scientists from around the globe will come together at Heart Rhythm 2015 to learn about innovations in science, education, and technology from the world's most noted experts on heart rhythm disorders.
Greg Cash, BioSig's President and CEO, said, "For more than 35 years, the Heart Rhythm Society has been on the forefront of advancements in cardiac electrophysiology. We are proud to participate in this prestigious meeting."
BioSig will be hosting an opportunity for those interested in meeting the Company's management and members of its Board on May 14, 2015 from 6:00 – 9:00pm at the Boston Harbor Hotel, 70 Rowes Wharf, on the 9th floor Rotunda. To attend, please contact Brian McLaughlin, VP of Corporate Finance and Investor Relations at email@example.com or call (917) 370-9817. The event will be co-sponsored by Laidlaw & Co (UK) Ltd., BioSig's investment banking partner since 2011. Laidlaw senior management will be in attendance.
About BioSig Technologies
BioSig Technologies is a medical device company that has developed a proprietary technology platform designed to greatly improve the $3 billion electrophysiology (EP) marketplace(1). Led by a proven management team and a veteran, independent Board of Directors, Minnesota-based BioSig Technologies is preparing to commercialize its PURE EP System.
PURE EP™ System is a next-generation surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing guidance in identifying ablation targets -- areas of tissue to destroy that otherwise create a heart rhythm disturbance (arrhythmia).
Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 2019(1) -- making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017(2).
BioSig intends to seek FDA 510(k) approval for the PURE EP(TM) System. The Company has already achieved proof of concept validation through UCLA EP & Animal Labs, and is collaborating with several of the nation's most prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UCLA Cardiac Arrhythmia Center, and Mayo Clinic.
Forward-Looking Statements This release includes forward-looking statements. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, regulatory approvals, competition and marketplace demand. More information, and BioSig risk factors, are set forth in its filings with the SEC. BioSig assumes no obligation to publicly update or revise its forward-looking statements.
(1) Electrophysiology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
(2) HRI 2013 "Global Opportunities in Medical Devices & Diagnostics" report; triangulation of multiple sources; *AF includes left atrial tachycardia, left WPW, left atrial flutter.
Source:BioSig Technologies, Inc.